Diaz-Canel pays tribute to prominent Cuban scientist
especiales

One of his contributions was the development of the first monoclonal antibodies in 1981, like Itolizumab, known for its goods results in treating severe Covid-19 patients.
Gavilondo's professional background included cellular and molecular biology, experimental immunology, recombinant and monoclonal antibodies, experimental oncology, vaccines against cancer, cellular radiobiology, cell culture and diagnostic systems.
Under his leadership, the Genetic Engineering and Biotechnology Center in Havana obtained the therapeutical vaccine against cancer, HeberSaVax, today on clinical trials.
He was also president of the Latin American Immunology Association, disseminated the results of Cuban biotechnology and represented the country before organizations and at international events.
Gavilondo received many prizes and recognitions, especially the Carlos J. Finlay Order, granted by the Council of State of Cuba.
In addition, he published some 150 scientific articles, seven patents and five books over 40 years of professional career.
Add new comment